Literature DB >> 21688085

High serum potassium levels after using losartan can reflect more severe renal disease.

A R Gonçalves, A M El Nahas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21688085     DOI： 10.1007/s00125-011-2220-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  7 in total

1.  Erythropoietin deficiency in hyporeninemia.

Authors:  S Donnelly; B R Shah
Journal:  Am J Kidney Dis       Date:  1999-05       Impact factor: 8.860

2.  The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis.

Authors:  A Bohle; M Wehrmann; O Bogenschütz; C Batz; C A Müller; G A Müller
Journal:  Pathol Res Pract       Date:  1991-03       Impact factor: 3.250

3.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate.

Authors:  R Nosadini; M Velussi; E Brocco; M Bruseghin; C Abaterusso; A Saller; M Dalla Vestra; A Carraro; E Bortoloso; M Sambataro; I Barzon; F Frigato; B Muollo; M Chiesura-Corona; G Pacini; B Baggio; F Piarulli; A Sfriso; P Fioretto
Journal:  Diabetes       Date:  2000-03       Impact factor: 9.461

5.  Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Authors:  Y Miao; D Dobre; H J Lambers Heerspink; B M Brenner; M E Cooper; H-H Parving; S Shahinfar; D Grobbee; D de Zeeuw
Journal:  Diabetologia       Date:  2010-09-30       Impact factor: 10.122

6.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

7.  ACE-inhibitor use and the long-term risk of renal failure in diabetes.

Authors:  S Suissa; T Hutchinson; J M Brophy; A Kezouh
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612
  7 in total
  1 in total

1.  Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.

Authors:  Sunil Bhandari; Natalie Ives; Elizabeth A Brettell; Marie Valente; Paul Cockwell; Peter S Topham; John G Cleland; Arif Khwaja; Meguid El Nahas
Journal:  Nephrol Dial Transplant       Date:  2015-09-30       Impact factor: 5.992
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.